Orthofix Medical Inc. Business Acquisition, Pro Forma Revenue
Orthofix Medical Inc. (OFIX) reported Business Acquisition, Pro Forma Revenue of $746.60 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-05.
Discontinued › Income Statement › Other Income
us-gaap:BusinessAcquisitionsProFormaRevenue · last filed 2024-03-05
- Orthofix Medical Inc. business acquisition, pro forma revenue for the quarter ending 2023-12-31 was $200.40M, a 7.97% increase year-over-year.
- Orthofix Medical Inc. business acquisition, pro forma revenue for the quarter ending 2023-09-30 was $184.00M, a 1.60% increase year-over-year.
- Orthofix Medical Inc. business acquisition, pro forma revenue for the quarter ending 2023-06-30 was $187.00K, a 7.22% increase year-over-year.
- Orthofix Medical Inc. business acquisition, pro forma revenue for the quarter ending 2023-03-31 was $175.20M, a 11.52% increase year-over-year.
- Orthofix Medical Inc. business acquisition, pro forma revenue for fiscal 2023 was $746.60M, a 6.93% increase from fiscal 2022.
- Orthofix Medical Inc. business acquisition, pro forma revenue for fiscal 2022 was $698.20M.
| Period end | Business Acquisition, Pro Forma Revenue 3 month | Business Acquisition, Pro Forma Revenue 6 month | Business Acquisition, Pro Forma Revenue 9 month | Business Acquisition, Pro Forma Revenue 12 month |
|---|---|---|---|---|
| 2023-12-31 | $200.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $384.40M derived: sum of 2 quarters · filed 2024-03-05 | $384.59M derived: sum of 3 quarters · filed 2024-03-05 | $746.60M 10-K · filed 2024-03-05 |
| 2023-09-30 | $184.00M 10-Q · filed 2023-11-08 | $184.19M derived: sum of 2 quarters · filed 2023-11-08 | $546.20M 10-Q · filed 2023-11-08 | $544.99M derived: sum of 4 quarters · filed 2024-03-05 |
| 2023-06-30 | $187.00K 10-Q · filed 2023-08-08 | $362.20K 10-Q · filed 2023-08-08 | $360.99M derived: sum of 3 quarters · filed 2024-03-05 | $542.09M derived: sum of 4 quarters · filed 2024-03-05 |
| 2023-03-31 | $175.20M 10-Q · filed 2023-05-09 | $360.80M derived: sum of 2 quarters · filed 2024-03-05 | $541.90M derived: sum of 3 quarters · filed 2024-03-05 | $542.07M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-12-31 | $185.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $366.70M derived: sum of 2 quarters · filed 2024-03-05 | $366.87M derived: sum of 3 quarters · filed 2024-03-05 | $698.20M 10-K · filed 2024-03-05 |
| 2022-09-30 | $181.10M 10-Q · filed 2023-11-08 | $181.27M derived: sum of 2 quarters · filed 2023-11-08 | $512.60M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $174.40K 10-Q · filed 2023-08-08 | $331.50K 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $157.10M 10-Q · filed 2023-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| CARLSMED, INC. (CARL) | United States | $0.405B | |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| ClearPoint Neuro, Inc. (CLPT) | United States | $0.446B | -15.74 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |